Pharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion?

Mike Greaves

Research output: Contribution to journalEditorialpeer-review

10 Citations (Scopus)
3 Downloads (Pure)

Abstract

Warfarin and related coumarin-based anticoagulants are the mainstay of pharmacological management for the long-term prevention of thromboembolism. It is estimated that over 1 million residents in the United Kingdom take warfarin; in excess of 20 million prescriptions for the anticoagulant are dispensed each year in the United States of America. Despite recent advances in the development of novel, alternative, oral antithrombotics it is likely that coumarins will be used widely for at least the next decade.
Original languageEnglish
Article numbere342
Number of pages2
JournalPLoS Medicine
Volume2
Issue number10
DOIs
Publication statusPublished - 25 Oct 2005

Fingerprint Dive into the research topics of 'Pharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion?'. Together they form a unique fingerprint.

Cite this